Literature DB >> 28671348

Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S.

B Dahlbäck1.   

Abstract

Factor V (FV) is a regulator of both pro- and anticoagulant pathways. It circulates as a single-chain procofactor, which is activated by thrombin or FXa to FVa that serves as cofactor for FXa in prothrombin activation. The cofactor function of FVa is regulated by activated protein C (APC) and protein S. FV can also function as an anticoagulant APC cofactor in the inhibition of FVIIIa in the membrane-bound tenase complex (FIXa/FVIIIa). In recent years, it has become clear that FV also functions in multiple ways in the tissue factor pathway inhibitor (TFPI) anticoagulant pathway. Of particular importance is a FV splice variant (FV-Short) that serves as a carrier and cofactor to TFPIα in the inhibition of FXa. FV-Short is generated through alternative splicing of exon 13 that encodes the large activation B domain. A highly negatively charged binding site for TFPIα is exposed in the C-terminus of the FV-Short B domain, which binds the positively charged C-terminus of TFPIα, thus keeping TFPIα in circulation. The binding of TFPIα to FV-Short is also instrumental in localizing the inhibitor to the surface of negatively charged phospholipids, where TFPIα inhibits FXa in process that is stimulated by protein S. Plasma FV activation intermediates and partially proteolyzed platelet FV similarly bind TFPIα with high affinity and regulate formation of prothrombinase. The novel insights gained into the interaction between FV isoforms, TFPIα, and protein S have opened a new avenue for research about the mechanisms of coagulation regulation and also for future development of therapeutics aimed at modulating coagulation.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  zzm321990TFPIzzm321990αzzm321990; blood coagulation; factor V; factor Xa; protein C; protein S

Mesh:

Substances:

Year:  2017        PMID: 28671348     DOI: 10.1111/jth.13665

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis.

Authors:  Hina Ogawa; Masayoshi Souri; Kazunori Kanouchi; Tsukasa Osaki; Rie Ohkubo; Tomoko Kawanishi; Sachiko Wakai; Keita Morikane; Akitada Ichinose
Journal:  Int J Hematol       Date:  2018-11-16       Impact factor: 2.490

2.  Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency.

Authors:  Dino Mehic; Alexander Tolios; Stefanie Hofer; Cihan Ay; Helmuth Haslacher; Judit Rejtö; Willem H Ouwehand; Kate Downes; Matthias Haimel; Ingrid Pabinger; Johanna Gebhart
Journal:  Blood Adv       Date:  2021-01-26

Review 3.  Novel treatments for hemophilia through rebalancing of the coagulation cascade.

Authors:  Yakun Zhao; Angela C Weyand; Jordan A Shavit
Journal:  Pediatr Blood Cancer       Date:  2021-02-12       Impact factor: 3.167

4.  Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress.

Authors:  Robert Ariens; Cecilia Becattini; Markus Bender; Wolfgang Bergmeier; Elisabetta Castoldi; Katrien Devreese; Martin Ellis; David Gailani; Vera Ignjatovic; Paula D James; Steven Kerrigan; Michele Lambert; Lai Heng Lee; Marcel Levi; Norma Maugeri; Joost Meijers; Juan Melero-Martin; Alan D Michelson; Federico Mingozzi; Keith Neeves; Heyu Ni; Anna-Karin Olsson; Zoltán Prohászka; Marie Ranson; Nicoletta Riva; Yotis Senis; Cornelia H van Ommen; Douglas E Vaughan; John Weisel
Journal:  Res Pract Thromb Haemost       Date:  2020-07-12

5.  The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex.

Authors:  Magdalena Gierula; Isabelle I Salles-Crawley; Salvatore Santamaria; Adrienn Teraz-Orosz; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Thromb Haemost       Date:  2019-08-09       Impact factor: 5.824

Review 6.  Platelets, Constant and Cooperative Companions of Sessile and Disseminating Tumor Cells, Crucially Contribute to the Tumor Microenvironment.

Authors:  Wolfgang M J Obermann; Katrin Brockhaus; Johannes A Eble
Journal:  Front Cell Dev Biol       Date:  2021-04-16

7.  Case Report and Literature Review: Behçet's Disease With a Novel TFPI Gene Mutation.

Authors:  Jiewen Ma; Wengang Sun; Liang Tang; Di Yang
Journal:  Front Med (Lausanne)       Date:  2022-04-19

8.  Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa.

Authors:  Anja Maag; Nienke van Rein; Tim J Schuijt; Wil F Kopatz; Danielle Kruijswijk; Stella Thomassen; Tilman M Hackeng; Rodney M Camire; Tom van der Poll; Joost C M Meijers; Mettine H A Bos; Cornelis van 't Veer
Journal:  J Thromb Haemost       Date:  2021-11-23       Impact factor: 16.036

9.  Thrombin generation abnormalities in Quebec platelet disorder.

Authors:  Justin G Brunet; Tanmya Sharma; Subia Tasneem; Minggao Liang; Michael D Wilson; Georges E Rivard; Catherine P M Hayward
Journal:  Int J Lab Hematol       Date:  2020-08-06       Impact factor: 2.877

Review 10.  Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.

Authors:  Rami A Al-Horani
Journal:  Am J Cardiovasc Drugs       Date:  2020-12       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.